Aliases & Classifications for Polyneuropathy

Summaries for Polyneuropathy

Disease Ontology : 12 A peripheral system disease that is characterized by is damage affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, pins-and-needles, and burning pain.

MalaCards based summary : Polyneuropathy, also known as polyneuropathies, is related to amyloidosis, hereditary, transthyretin-related and polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, and has symptoms including neuralgia An important gene associated with Polyneuropathy is GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Imipramine and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral... more...

Related Diseases for Polyneuropathy

Diseases in the Polyneuropathy family:

Polyneuropathy Due to Drug Chronic Polyneuropathy

Diseases related to Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1173)
# Related Disease Score Top Affiliating Genes
1 amyloidosis, hereditary, transthyretin-related 34.6 TTR GSN APOA1
2 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 34.6 PNPLA6 ABHD12
3 demyelinating polyneuropathy 34.6 TTR PMP22 MAG
4 chronic inflammatory demyelinating polyradiculoneuropathy 34.5 PMP22 MPZ MBP CD59
5 chronic polyneuropathy 34.5 PMP22 MAG CD40LG
6 guillain-barre syndrome 34.3 PMP22 MPZ MBP CD40LG
7 neuropathy, hereditary, with liability to pressure palsies 34.0 PRX PMP22 MPZ MAG GDAP1
8 diabetic neuropathy 33.5 PMP22 MPZ AKR1B1
9 charcot-marie-tooth disease, demyelinating, type 1b 33.2 PRX PMP22 MPZ GDAP1
10 hypertrophic neuropathy of dejerine-sottas 33.2 PRX PMP22 MPZ MBP MAG GDAP1
11 polyradiculoneuropathy 33.0 PMP22 MPZ MBP MAG CD59 CD40LG
12 charcot-marie-tooth disease 32.9 PRX POLG PMP22 MT-ATP6 MPZ MBP
13 neuropathy 32.6 PRX POLG PNPLA6 PMP22 MT-ATP6 MPZ
14 amyloidosis 32.2 TTR GSN CD40LG APOA1
15 miller fisher syndrome 32.2 PMP22 MAG CD40LG
16 peripheral nervous system disease 31.8 TTR PRX POLG PNPLA6 PMP22 MT-ATP6
17 charcot-marie-tooth disease, demyelinating, type 1a 31.8 PRX PMP22 MPZ MAG GDAP1
18 axonal neuropathy 31.8 POLG PMP22 GDAP1
19 carpal tunnel syndrome 31.8 TTR PMP22 MPZ
20 motor peripheral neuropathy 31.7 PMP22 MAG GDAP1
21 roussy-levy hereditary areflexic dystasia 31.7 PMP22 MPZ
22 charcot-marie-tooth disease, type 4a 31.6 PRX MPZ GDAP1
23 charcot-marie-tooth disease, type 4b2 31.6 PRX MPZ GDAP1
24 charcot-marie-tooth disease, type 4b1 31.6 PRX MPZ GDAP1
25 neuropathy, congenital hypomyelinating, 1, autosomal recessive 31.5 PRX PMP22 MPZ GDAP1
26 hereditary amyloidosis 31.5 TTR GSN APOA1
27 mononeuropathy 31.4 PMP22 MPZ MAG CD40LG
28 osteosclerotic myeloma 31.4 MAG CD40LG
29 tooth disease 31.4 PRX PMP22 MT-ATP6 MPZ GDAP1
30 foot drop 31.3 PMP22 MPZ
31 mononeuritis multiplex 31.3 PMP22 MAG CD40LG
32 hereditary neuropathies 31.3 PRX PMP22 MPZ MBP MAG
33 neuritis 31.3 PMP22 MPZ MBP MAG
34 sensory peripheral neuropathy 31.3 PRX POLG PMP22 MPZ MAG GDAP1
35 kearns-sayre syndrome 31.2 SPG7 POLG MT-ATP6 MAG
36 charcot-marie-tooth disease, axonal, type 2i 31.1 PMP22 MPZ GDAP1
37 polyradiculopathy 31.1 PMP22 CD40LG AKR1B1
38 charcot-marie-tooth disease, dominant intermediate e 31.1 MPZ GDAP1
39 charcot-marie-tooth disease, axonal, type 2a1 31.1 MPZ GDAP1
40 charcot-marie-tooth disease, axonal, type 2j 31.0 MPZ GDAP1
41 charcot-marie-tooth disease, dominant intermediate a 31.0 PRX MPZ GDAP1
42 charcot-marie-tooth disease, demyelinating, type 4f 31.0 PRX MPZ GDAP1
43 charcot-marie-tooth disease, type 4h 30.9 PRX MPZ GDAP1
44 plexopathy 30.9 PMP22 CD40LG
45 charcot-marie-tooth disease, axonal, type 2l 30.9 MPZ GDAP1
46 optic neuritis 30.9 MPZ MBP MAG
47 autoimmune neuropathy 30.9 PMP22 MPZ MAG CD40LG
48 charcot-marie-tooth disease, demyelinating, type 1d 30.9 PRX PMP22 MPZ GDAP1
49 charcot-marie-tooth disease, x-linked dominant, 1 30.9 PRX PMP22 MPZ GDAP1
50 charcot-marie-tooth disease, demyelinating, type 1c 30.9 PRX PMP22 MPZ GDAP1

Graphical network of the top 20 diseases related to Polyneuropathy:



Diseases related to Polyneuropathy

Symptoms & Phenotypes for Polyneuropathy

UMLS symptoms related to Polyneuropathy:


neuralgia

GenomeRNAi Phenotypes related to Polyneuropathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.07 GSN
2 Decreased viability GR00240-S-1 10.07 CD40LG CD59
3 Decreased viability GR00381-A-1 10.07 MPZ PRX
4 Decreased viability GR00381-A-3 10.07 MPZ
5 Decreased viability GR00402-S-2 10.07 ABHD12 AKR1B1 APOA1 ARSA CD40LG CD59
6 no effect GR00402-S-1 9.62 ABHD12 AKR1B1 APOA1 ARSA CD40LG CD59

MGI Mouse Phenotypes related to Polyneuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 ABHD12 AKR1B1 APOA1 ARSA CD40LG CD59
2 behavior/neurological MP:0005386 10.18 ABHD12 AKR1B1 ARSA DMXL2 GDAP1 MAG
3 cellular MP:0005384 10.11 APOA1 CD40LG CD59 GDAP1 GSN MBP
4 hematopoietic system MP:0005397 10.06 ABHD12 ARSA CD40LG CD59 GDAP1 GSN
5 nervous system MP:0003631 9.83 ABHD12 ARSA CD40LG DMXL2 GDAP1 GSN
6 integument MP:0010771 9.76 APOA1 CD40LG GDAP1 GSN MPZ PNPLA6
7 reproductive system MP:0005389 9.28 CD40LG CD59 DMXL2 GDAP1 GSN MBP

Drugs & Therapeutics for Polyneuropathy

Drugs for Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imipramine Approved Phase 4 50-49-7 3696
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Citalopram Approved Phase 4 59729-33-8 2771
5
Oxcarbazepine Approved Phase 4 28721-07-5 34312
6
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
7
Nortriptyline Approved Phase 4 72-69-5 4543
8
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
9
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
14
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
15
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
18
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
19 Anti-Asthmatic Agents Phase 4
20 Platelet Aggregation Inhibitors Phase 4
21 Autonomic Agents Phase 4
22 Vasodilator Agents Phase 4
23 Neuroprotective Agents Phase 4
24 Bronchodilator Agents Phase 4
25 Protective Agents Phase 4
26 Phosphodiesterase Inhibitors Phase 4
27 Phosphodiesterase 3 Inhibitors Phase 4
28 Hormone Antagonists Phase 4
29 Acetylcholine Release Inhibitors Phase 4
30 Neuromuscular Agents Phase 4
31 Botulinum Toxins Phase 4
32 abobotulinumtoxinA Phase 4
33 Cholinergic Agents Phase 4
34 Botulinum Toxins, Type A Phase 4
35 Gastrointestinal Agents Phase 4
36 Antioxidants Phase 4
37 Vitamins Phase 4
38 Trace Elements Phase 4
39 Nutrients Phase 4
40 Vitamin B Complex Phase 4
41 Vitamin B9 Phase 4
42 Micronutrients Phase 4
43 Folate Phase 4
44 Serotonin Uptake Inhibitors Phase 4
45 Parasympatholytics Phase 4
46 Muscarinic Antagonists Phase 4
47 Serotonin Agents Phase 4
48 Cholinergic Antagonists Phase 4
49 Alpha-lipoic Acid Phase 4
50 Thioctic Acid Phase 4

Interventional clinical trials:

(show top 50) (show all 304)
# Name Status NCT ID Phase Drugs
1 Randomised, Double-blind, Placebo-controlled Trial of the Effect of the Combination of Imipramine and Pregabalin for the Treatment of Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
2 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
4 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
5 Effects of Pregabalin on Mechanical Hyperalgesia - EPOM Unknown status NCT00310583 Phase 4 Pregabalin
6 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
7 Double-blind, Randomised, Placebo-controlled Trial of the Effect of Levetiracetam on Painful Polyneuropathy Completed NCT00286260 Phase 4 levetiracetam
8 Escitalopram as a Treatment for Pain in Polyneuropathy. A Double-Blind, Randomized, Placebo Controlled Trial. Completed NCT00162968 Phase 4 escitalopram
9 Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain: Predictors of Response - a Randomised, Double-blind, Placebo-controlled Clinical Trial Completed NCT01302275 Phase 4 Oxcarbazepine
10 Qutenza Versus Pregabalin in Subjects With Peripheral Neuropathic Pain: an Open-label, Randomized, Multicenter, Non-inferiority Efficacy and Tolerability Study Completed NCT01713426 Phase 4 Qutenza;Pregabalin
11 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
12 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm
13 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
14 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
15 Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
16 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
17 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
18 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
19 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
20 Local Steroid Injection vs Wrist Splinting for Carpal Tunnel Syndrome: A Randomized Clinical Trial Completed NCT02140632 Phase 4
21 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
22 Comparison of the Efficacy of Corticosteroid Injection and Extracorporeal Shock Wave Therapy (ESWT) in Patients With Carpal Tunnel Syndrome; A Prospective Randomized Controlled Trial Not yet recruiting NCT03792945 Phase 4 local injection
23 A Double-blind, Placebo-controlled, Cross-over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy Terminated NCT00832572 Phase 4 Ranolazine;Placebo
24 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
25 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
26 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Thioctacid Oral Tablet 600mg Once Daily in Chinese Diabetic Patients With Distal Symmetric Polyneuropathy Unknown status NCT01224353 Phase 2, Phase 3 lipoic acid
27 Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness Unknown status NCT02706587 Phase 3
28 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
29 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months. Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
30 Pilot Randomized, Controlled Trial of Testosterone Therapy in Chronic Critically Ill Patients and Its Potential Effects on Weaning From Mechanical Ventilation and Intensive Care Unit-acquired Weakness Unknown status NCT03038919 Phase 2, Phase 3 Testosterone cypionate
31 Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Completed NCT00101426 Phase 3 ranirestat, (AS-3201)
32 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
33 A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin® in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy Completed NCT00483730 Phase 3 Deproteinised hemoderivative of calf blood (Actovegin)
34 The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study Completed NCT01435655 Phase 3 tafamidis
35 A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy Completed NCT00927914 Phase 2, Phase 3 Ranirestat;Placebo
36 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
37 Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
38 APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) Completed NCT01960348 Phase 3 patisiran (ALN-TTR02);Sterile Normal Saline (0.9% NaCl)
39 A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
40 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
41 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-Blind,Placebo-Controlled Multicentre Trial With 4 Parallel Groups Completed NCT00328601 Phase 3 Thioctic Acid
42 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
43 A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study) Completed NCT01737398 Phase 2, Phase 3 Inotersen;Placebo
44 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
45 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
46 Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study Completed NCT01263132 Phase 3 F0434;Gabapentin
47 Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
48 Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study Completed NCT01465620 Phase 3
49 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
50 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)

Search NIH Clinical Center for Polyneuropathy

Cochrane evidence based reviews: polyneuropathies

Genetic Tests for Polyneuropathy

Anatomical Context for Polyneuropathy

MalaCards organs/tissues related to Polyneuropathy:

40
Liver, Testes, Skin, Heart, Bone, T Cells, Spinal Cord

Publications for Polyneuropathy

Articles related to Polyneuropathy:

(show top 50) (show all 13848)
# Title Authors PMID Year
1
An alternative in vitro method for detecting neuropathic compounds based on acetylcholinesterase inhibition and on inhibition and aging of neuropathy target esterase (NTE). 54 61
20097283 2010
2
Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells. 54 61
20015874 2010
3
[Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report]. 54 61
20305976 2010
4
[Anti-MAG paraproteinemic demyelinating polyneuropathy: a clinical, biological, electrophysiological and anatomopathological descriptive study of a 13-patients' cohort]. 54 61
19487003 2009
5
Neuromuscular disease presentation with three genetic defects involving two genomes. 54 61
19853445 2009
6
Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy. 54 61
19790249 2009
7
Hereditary gelsolin amyloidosis mimicking Sjögren's syndrome. 54 61
19701715 2009
8
Clusterin regulates transthyretin amyloidosis. 54 61
19664600 2009
9
Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. 54 61
19720975 2009
10
Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin. 54 61
19266164 2009
11
Severe demyelinating hypertrophic polyneuropathy caused by a de novo frameshift mutation within the intracellular domain of myelin protein zero (MPZ/P0). 54 61
19344920 2009
12
SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. 54 61
19372189 2009
13
Immunoglobulin M deposition in cutaneous nerves of anti-myelin-associated glycoprotein polyneuropathy patients correlates with axonal degeneration. 54 61
19151627 2009
14
Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. 54 61
19050296 2008
15
Transthyretin forms amyloid fibrils at physiological pH with ultrasonication. 54 61
19065294 2008
16
Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. 54 61
19065295 2008
17
[Spectrum and frequency of mutations in the connexin 32 gene (GJB1) in hereditary and sensory neuropathy type 1X patients from Bashkortostan]. 54 61
19062535 2008
18
Increased severity over generations of Charcot-Marie-Tooth disease type 1A. 54 61
18438698 2008
19
Unusual presentation of hereditary neuropathy with liability to pressure palsies. 54 61
18218131 2008
20
[Diagnosis of familial amyloid polyneuropathy type I in Argentina]. 54 61
18786882 2008
21
Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. 54 61
18186575 2008
22
Transthyretin amyloid goiter in a renal allograft recipient. 54 61
18369743 2008
23
Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related. 54 61
18776590 2008
24
Rapid progression of late onset axonal Charcot-Marie-Tooth disease associated with a novel MPZ mutation in the extracellular domain. 54 61
17940173 2007
25
Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. 54 61
17724793 2007
26
Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. 54 61
17875187 2007
27
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 54 61
17923639 2007
28
Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. 54 61
17714186 2007
29
Combined heart and liver transplantation for familial amyloidotic neuropathy. 54 61
17449267 2007
30
DJ-1 degrades transthyretin and an inactive form of DJ-1 is secreted in familial amyloidotic polyneuropathy. 54 61
17487420 2007
31
Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. 54 61
17565535 2007
32
Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. 54 61
17381508 2007
33
The search of the target of promotion: Phenylbenzoate esterase activities in hen peripheral nerve. 54 61
17207828 2007
34
NDRG1-linked Charcot-Marie-Tooth disease (CMT4D) with central nervous system involvement. 54 61
17142040 2007
35
Destabilization of transthyretin by pathogenic mutations in the DE loop. 54 61
17143887 2007
36
Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. 54 61
17206084 2007
37
Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. 54 61
16967492 2007
38
Do carbamates cause polyneuropathy? 54 61
16897762 2006
39
Novel myelin protein zero mutation (Arg36Trp) in a patient with acute onset painful neuropathy. 54 61
16616847 2006
40
Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. 54 61
16515552 2006
41
Current issues in organophosphate toxicology. 54 61
16337171 2006
42
Phenotypic and cellular expression of two novel connexin32 mutations causing CMT1X. 54 61
16476939 2006
43
Peripheral neuropathies in Waldenström's macroglobulinaemia. 54 61
16421127 2006
44
Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. 54 61
16386248 2006
45
A Swedish family with the rare Phe33Leu transthyretin mutation. 54 61
16194875 2005
46
Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis. 54 61
16101296 2005
47
Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. 54 61
15689188 2005
48
Dimeric transthyretin variant assembles into spherical neurotoxins. 54 61
15736938 2005
49
Adult onset metachromatic leukodystrophy without electroclinical peripheral nervous system involvement: a new mutation in the ARSA gene. 54 61
15710861 2005
50
Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. 54 61
15281912 2005

Variations for Polyneuropathy

ClinVar genetic disease variations for Polyneuropathy:

6 (show all 12) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SPG7 NM_003119.4(SPG7):c.87G>A (p.Trp29Ter)SNV Pathogenic 689557 16:89574912-89574912 16:89508504-89508504
2 GDAP1 NM_018972.4(GDAP1):c.715C>T (p.Leu239Phe)SNV Pathogenic 4200 rs104894080 8:75276240-75276240 8:74364005-74364005
3 ERCC5 NM_000123.3(ERCC5):c.2927_2928CT[1] (p.Leu977fs)short repeat Likely pathogenic 373982 rs1057518813 13:103525655-103525656 13:102873305-102873306
4 MED25 NM_030973.3(MED25):c.2088G>A (p.Leu696=)SNV Conflicting interpretations of pathogenicity 221058 rs371157406 19:50339605-50339605 19:49836348-49836348
5 MED25 NM_030973.3(MED25):c.305+14C>GSNV Uncertain significance 689579 19:50322567-50322567 19:49819310-49819310
6 MED25 NM_030973.3(MED25):c.1086C>T (p.Pro362=)SNV Uncertain significance 689543 19:50334129-50334129 19:49830872-49830872
7 REEP1 NM_001371279.1(REEP1):c.789G>A (p.Pro263=)SNV Uncertain significance 694650 2:86444228-86444228 2:86217105-86217105
8 SMC1A NM_001281463.1(SMC1A):c.2915A>G (p.Gln972Arg)SNV Uncertain significance 373969 rs781817923 X:53410167-53410167 X:53383246-53383246
9 TGM6 NM_198994.3(TGM6):c.691C>T (p.Arg231Ter)SNV Uncertain significance 437001 rs201338900 20:2380225-2380225 20:2399579-2399579
10 LMNA NM_170707.4(LMNA):c.1270A>C (p.Thr424Pro)SNV Uncertain significance 689547 1:156106117-156106117 1:156136326-156136326
11 DYNC1H1 NM_001376.5(DYNC1H1):c.2539-10C>ASNV Uncertain significance 689550 14:102453780-102453780 14:101987443-101987443
12 POLG NM_002693.2(POLG):c.2982G>C (p.Trp994Cys)SNV Uncertain significance 689545 15:89862581-89862581 15:89319350-89319350

Expression for Polyneuropathy

Search GEO for disease gene expression data for Polyneuropathy.

Pathways for Polyneuropathy

Pathways related to Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.4 MAG GSN GDAP1
2 11.14 PMP22 MPZ MBP
3 9.53 MBP MAG

GO Terms for Polyneuropathy

Cellular components related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.2 SPG7 SLC25A19 PRX POLG PNPLA6 PMP22
2 extracellular space GO:0005615 9.86 TTR GSN DMXL2 CD59 CD40LG ARSA
3 myelin sheath GO:0043209 9.26 MPZ MBP MAG GSN
4 Schmidt-Lanterman incisure GO:0043220 9.16 MAG AKR1B1
5 compact myelin GO:0043218 8.8 PMP22 MBP MAG

Biological processes related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hyperoxia GO:0055093 9.43 POLG MT-ATP6
2 glycerophospholipid catabolic process GO:0046475 9.4 PNPLA6 ABHD12
3 phosphatidylcholine metabolic process GO:0046470 9.37 PNPLA6 APOA1
4 retinoid metabolic process GO:0001523 9.33 TTR APOA1 AKR1B1
5 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.32 MPZ MAG
6 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.26 MBP APOA1
7 myelination GO:0042552 9.13 PMP22 MPZ MBP
8 axon ensheathment GO:0008366 8.62 PRX MBP

Molecular functions related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysophospholipase activity GO:0004622 8.62 PNPLA6 ABHD12

Sources for Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....